WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, September 19, 2006

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L5	L4 and piperidin$5	19
☐	L4	L3 and benzimidaz$5	38
☐	L3	deacetylase	726
☐	L2	L1 and deacetylase	0
☐	L1	546/199.ccls.	880

END OF SEARCH HISTORY

=> d 18
L8 HAS NO ANSWERS
L8 STR





VAR G1=10/11/12
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 16
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 11 9
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l8 ful
FULL SEARCH INITIATED 10:48:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18139 TO ITERATE

100.0% PROCESSED 18139 ITERATIONS 123 ANSWERS
SEARCH TIME: 00.00.01

L10 123 SEA SSS FUL L8

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 169.14 248.21

FILE 'CAPLUS' ENTERED AT 10:48:51 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 19 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 18 Sep 2006 (20060918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L11 15 L10

=> d bib abs 1-15

L11 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1354729 CAPLUS
DN 144:88271
TI Preparation of tricyclic thienopyridine compounds as IKK2 inhibitors
IN Okamoto, Yoshinori; Hattori, Kazuyuki; Kubota, Hirokazu; Sato, Ippei; Kanayama, Takatoshi; Yokoyama, Kazuhiro; Terai, Yoshiya; Takeuchi, Masahiro
PA Astellas Pharma Inc., Japan; Kotobuki Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005123745	A1	20051229	WO 2005-JP11325	20050621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2004-183073 A 20040621
OS MARPAT 144:88271
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = Q1, -NR2R3; Het = saturated heterocycle containing nitrogen;
R1 = alkyl, halo, haloalkyl, etc.; k = 0-3; when Het is morpholino group, k is 1-3; R2, R3 = H, alkyl, -alkylene-OR6, etc.; R6 = H, alkyl; ; X = -CR7R8-, -O-, -CO-, etc.; R7, R8 = H, alkyl, halo, etc.; m = 0-3; n = 0-3 such as $2 \leq m+n \leq 5$] were prepared For example, reaction of tert-Bu 3-(4-cyano-3-thioxo-2,3,5,6,7,8-hexahydroisoquinolin-1-yl)piperidine-1-carboxylate, e.g., prepared from cyanothioacetamide, with 2-bromoacetamide followed by treatment with HCl/dioxane afforded compound II·HCl [A = piperidin-3-yl; Y = H]. In IKK2 inhibition assays, the

IC50 value of compound II·2HCl [A = piperazin-1-yl; Y = methyl] was 11 nM. Compds. I are claimed useful for the treatment of inflammation, autoimmune diseases.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:547272 CAPLUS
DN 143:103191
TI Histone deacetylase inhibitors for treatment of neoplastic and inflammatory disorders
IN Bressi, Jerome C.; Gangloff, Anthony R.; Jennings, Andrew J.
PA Syrrx, Inc., USA
SO U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005137234	A1	20050623	US 2004-13234	20041214
WO 2005066151	A2	20050721	WO 2004-US42009	20041214
WO 2005066151	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-531371P P 20031219
OS MARPAT 143:103191
AB Histone deacetylase inhibitors and uses thereof are provided. Knowledge of the crystal structure of human histone deacetylase 8 (HDAC8) was used to guide the design of 114 chemical inhibitors. General synthetic schemes are also provided. The inhibitors are of use (no data) for treatment of various cancers, inflammation, inflammatory bowel disease, psoriasis, or transplant rejection.

L11 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:799454 CAPLUS
DN 141:291229
TI Histone deacetylase inhibitors
IN Bressi, Jerome C.; Brown, Jason W.; Cao, Sheldon X.; Gangloff, Anthony R.; Jennings, Andrew J.; Stafford, Jeffrey A.; Vu, Phong H.; Xiao, Xiao-Yi
PA Syrrx, Inc., USA
SO PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004082638	A2	20040930	WO 2004-US8342	20040317
WO 2004082638	A3	20050506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2518318		AA	20040930	CA 2004-2518318	20040317
US 2004254220		A1	20041216	US 2004-803575	20040317
US 2004266769		A1	20041230	US 2004-803344	20040317
US 2005137232		A1	20050623	US 2004-803580	20040317
EP 1608628		A2	20051228	EP 2004-757631	20040317
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1787999		A	20060614	CN 2004-80011872	20040317
JP 2006520796		T2	20060914	JP 2006-507336	20040317
PRAI US 2003-455437P		P	20030317		
US 2003-531203P		P	20031219		
WO 2004-US8342		W	20040317		

OS MARPAT 141:291229

AB Compds. that may be used to inhibit histone deacetylase are disclosed. Thus, 119 compds. were prepared which exhibited better than 1000 nM IC50 against HDAC1, HDAC2, HDAC6, and HDAC8 (suberanilohydroxamic acid showed an IC50 of 63 nM in this assay). Many of these compds. were 3-[3-(1-substituted-1H-benzoimidazol-2-yl)phenyl]acrylic acids and N-hydroxy-[3-(1-substituted-1H-benzoimidazol-2-yl)phenyl]acrylamides.

L11 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:855801 CAPLUS
DN 139:350734
TI Preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists
IN Zeng, Qingbei; Aslanian, Robert G.; Berlin, Michael Y.; Boyce, Christopher W.; Cao, Jianhua; Kozlowski, Joseph A.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.; Shih, Neng-Yang; Solomon, Daniel M.; Tom, Wing C.
PA Schering Corporation, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003088967	A1	20031030	WO 2003-US11672	20030416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481940	AA	20031030	CA 2003-2481940	20030416
AU 2003223627	A1	20031103	AU 2003-223627	20030416
US 2004097483	A1	20040520	US 2003-417391	20030416
US 7105505	B2	20060912		
EP 1499316	A1	20050126	EP 2003-719766	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009348	A	20050301	BR 2003-9348	20030416

	CN 1658874	A	20050824	CN 2003-813779	20030416
	JP 2005529116	T2	20050929	JP 2003-585719	20030416
	ZA 2004007984	A	20051018	ZA 2004-7984	20041004
	NO 2004005002	A	20050118	NO 2004-5002	20041117
PRAI	US 2002-373731P	P	20020418		
	US 2002-373467P	P	20020418		
	WO 2003-US11672	W	20030416		

OS MARPAT 139:350734

GI



I



II

AB The title compds. [I; R1 = (un)substituted benzimidazolyl or a derivative thereof; R2 = (un)substituted aryl or heteroaryl; M1, M2 = CR3, N; X = a bond, alkylene; Y = CO, CS, SO2, etc.; Z = a bond, alkylene, CO, etc.; R3 = H, halo, alkyl, etc.; R12 = alkyl, OH, alkoxy, etc.; R13 = alkyl, alkoxy, OH, etc.; a, b = 0-2; n, p = 1-3; r = 0-3; with the provisos] which are histamine H3 antagonists, were prepared E.g., a multi-step synthesis of II which showed Ki of 1 nM in rHu H3 binding assay, was given. Also disclosed are pharmaceutical compns. comprising the compds. of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I. Also disclosed are methods of treating said diseases or conditions using the compds. of formula I in combination with an H1 receptor antagonist.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:215662 CAPLUS

DN 139:133505

TI Solid-phase synthesis of benzimidazole libraries biased for RNA targets

AU Vourloumis, Dionisios; Takahashi, Masayuki; Simonsen, Klaus B.; Ayida, Benjamin K.; Barluenga, Sofia; Winters, Geoffrey C.; Hermann, Thomas

CS Department of Medicinal Chemistry, Anadys Pharmaceuticals, Inc., San Diego, CA, 92121, USA

SO Tetrahedron Letters (2003), 44(14), 2807-2811

CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 139:133505
GI



I II

AB An efficient and highly versatile synthesis of two libraries I (R1 = 3-pyridylmethyl, CH2CH2NMe2, N-morpholinylethyl, etc., R2 = 3-O2NC6H4, 3-pyridyl, 2-O2N-3-ClC6H3, etc.) and II [R = 4-C6H4CH2, (CH2)5, CH2, etc., R1 = CH2CH2CO2Et, N-morpholinylethyl, 5-methyl-2-furylmethyl, etc., R2 = 2-Cl-6-O2NC6H3, 3-thienyl, 2-Cl-5-O2N-C6H3, etc.; R2 = cyclohexyl, Et, PhCH2] based on the privileged benzimidazole scaffold is described. Our design is aimed at obtaining mols., biased for binding to RNA targets, by incorporating functionalities, which are frequently found in natural RNA-ligands. The library construction was realized with the use of SPOS (solid-phase organic synthesis) using either the Wang resin or the Rink amide resin in high average yields and purity. Monitoring and quantitation of intermediates and final products were performed by the use of NMR spectroscopy using DMFu as an internal standard

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:117042 CAPLUS
DN 132:151821
TI Preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists.
IN Ito, Fumitaka; Noguchi, Hirohide; Kondo, Hiroshi
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000008013	A2	20000217	WO 1999-IB1239	19990705
WO 2000008013	A3	20000323		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 513424	B	20021211	TW 1999-88110899	19990628
CA 2339621	AA	20000217	CA 1999-2339621	19990705

	CA 2339621	C	20050405		
	AU 9943859	A1	20000228	AU 1999-43859	19990705
	AU 749166	B2	20020620		
	EP 1102762	A2	20010530	EP 1999-926688	19990705
	EP 1102762	B1	20021113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100403	T2	20010723	TR 2001-200100403	19990705
	BR 9912778	A	20010925	BR 1999-12778	19990705
	EE 200100075	A	20020617	EE 2001-75	19990705
	JP 2002522431	T2	20020723	JP 2000-563646	19990705
	JP 3367945	B2	20030120		
	AT 227716	E	20021115	AT 1999-926688	19990705
	PT 1102762	T	20030228	PT 1999-926688	19990705
	ES 2185357	T3	20030416	ES 1999-926688	19990705
	NZ 509299	A	20030530	NZ 1999-509299	19990705
	US 6172067	B1	20010109	US 1999-369208	19990805
	ZA 2001000900	A	20020603	ZA 2001-900	20010201
	HR 2001000089	A1	20020228	HR 2001-89	20010202
	HR 20010089	B1	20030430		
	NO 2001000603	A	20010405	NO 2001-603	20010205
	BG 105301	A	20011231	BG 2001-105301	20010301
	US 2003109549	A1	20030612	US 2002-283604	20021030
PRAI	WO 1998-IB1206	W	19980806		
	WO 1999-IB1239	W	19990705		
	US 1999-369208	A3	19990805		
	US 2000-676245	B1	20000929		

OS MARPAT 132:151821

GI



I

AB Title compds. [I; R = (substituted) mono-, di-, tri-, or tetracycloalkyl; A = alkyl, haloalkyl, alkenyl, alkynyl, (substituted) phenylalkyl, aryl, heteroaryl, heterocyclyl; Y = H, halo, amino, SH, (substituted) alkyl-M, cycloalkyl-M, alkenyl-M, alkyl-NH-alkyl-M, dialkyl-N-alkyl-M, aryl-M, heterocyclyl-M, arylalkyl-M, etc.; M = bond, O, S, NH S, SO, SO2, etc.; Z1-Z4 = H, halo, alkyl, haloalkyl, alkoxy, alkylsulfonyl, alkylcarbonyl, CO2H, amino, H2NCO, Ph, naphthyl, etc.], were prepared as ORL1 receptor agonists (no data). Thus, 2-chloro-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]benzimidazole (preparation given) was stirred with MeNH2 in MeOH in an autoclave at 110° for 6 h to give N-methyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-amine.

L11 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:545375 CAPLUS

DN 129:148993

TI Preparation and formulation of ω-(heteroaryloxy)alkanamines as serotonin reuptake inhibitors and 5-HT1A receptor ligands

IN Audia, James E.; Hibschman, David J.; Krushinski, Joseph H., Jr.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly Co., USA
SO U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5789402	A	19980804	US 1995-471121	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		

OS MARPAT 129:148993
GI



I

AB Title compds. [I; R1 = (CH2)rCHXCH2(CH2)sR; r = 0-4; s = 0-1; D = a residue which combines with the carbon atoms to which it is attached to complete a pyrrolyl group; X = H, Ph, OH, MeO; R = (un)substituted piperazino, piperidino, etc.] were prepd as serotonin reuptake inhibitors and 5-HT1A receptor ligands (no data). Thus, refluxing of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-amino-1-benzylpiperidine in MeOH gave (2S)-(-)-I [R1 = CH2CH(OH)CH2R, R = 1-benzyl-4-piperidinylamino].
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:250697 CAPLUS
DN 128:294709
TI Heterocyclyloxyalkanamines having effects on serotonin-related systems
IN Hibschman, David J.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.
PA Eli Lilly and Co., USA
SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5741789	A	19980421	US 1995-467434	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
	US 6172073	B1	20010109	US 1998-49837	19980327
PRAI	US 1995-373823	B2	19950117		
	US 1995-467434	A3	19950606		

OS MARPAT 128:294709
GI



I



II

AB A series of heterocyclyloxy-substituted alkanamines I [m = 0-4; n = 0-1; D = atoms to complete fused pyrrolo, imidazolo, pyrido, pyrazino, pyridazino, or pyrimido nucleus (only pyrido is claimed); X = H, Ph, OH, OMe; X = H or Ph when m = 0; R = certain (un)substituted cyclic, bicyclic, and spirocyclic amino groups] are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor (no data). Some I show a unique combination of 5-HT1A receptor activity and serotonin reuptake inhibition. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used. Over 200 synthetic examples and 7 standard formulation examples are given. In the only example of a claimed compound (quinoline-derived, D = pyrido), reaction of (R)-5-(oxiranylmethoxy)quinoline with 6-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole in EtOH gave the preferred compound II in 87% yield.

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:344806 CAPLUS
DN 127:34133
TI Heterocyclyloxyalkanamines having effects on serotonin-related systems
IN Audia, James E.; Hibschman, David J.; Krushinski, Joseph H., Jr.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5627196	A	19970506	US 1995-468948	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		

OS MARPAT 127:34133
GI



I



II

AB A series of heterocyclyloxy-substituted alkanamines I [m = 0-4; n = 0-1; D = atoms to complete fused pyrrolo, imidazolo, pyrido, pyrazino, pyridazino, or pyrimido nucleus; X = H, Ph, OH, OMe; X = H or Ph when r = 0; R = (un)substituted piperidino, piperazino, piperidinylamino, piperazinoamino, morpholinoamino, certain spirocyclic amino substituents, etc.] are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor (no data). Some I show a unique combination of 5-HT1A receptor activity and serotonin reuptake inhibition. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used. Over 200 synthetic examples and 7 standard formulation examples are given. For instance, reaction of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-(3,4-methylenedioxyphenyl)piperidine gave a preferred title compound, II, isolated as the oxalate in 71% overall yield.

L11 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:260110 CAPLUS
DN 126:305591
TI Preparation of heteroaryloxy alkanamines having effects on serotonin-related systems
IN Audia, James E.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5614523	A	19970325	US 1995-470512	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		

OS MARPAT 126:305591
GI



I



II

AB The title compds. [I; r = 0-4; s = 0-1; D = a residue which combines with the carbon atoms to which it is attached to complete a pyrrolyl group; X = H, Ph, OH, MeO; R = (un)substituted piperazino, piperidino, etc.], useful for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor, were prepared and formulated. Thus, refluxing of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-amino-1-benzylpiperidine in MeOH afforded 78% (2S)-(-)-II. Compds. I are effective at 20-25 mg/day when administered to a patient in need of or carrying out a reduction or cessation of tobacco or nicotine use. Compds. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression, anxiety, hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders and obesity, substance abuse, obsessive-compulsive disorder, panic disorder, migraine, pain, bulimia, premenstrual syndrome, late luteal syndrome, alcoholism, dementia of aging, social phobia, attention deficit hyperactivity disorder, impulsive control disorders, chronic fatigue syndrome, premature ejaculation, anorexia nervosa, and autism.

L11 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:94071 CAPLUS
DN 126:104431
TI Preparation of heterocyclic dipeptide derivatives which promote release of growth hormone
IN Carpino, Philip A.; Jardine DaSilva, Paul A.; Lefker, Bruce A.; Ragan, John A.
PA Pfizer Inc., USA
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9638471	A1	19961205	WO 1995-IB410	19950529
	W: CA, FI, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2220055	AA	19961205	CA 1995-2220055	19950529
	CA 2220055	C	20010424		
	EP 828754	A1	19980318	EP 1995-918123	19950529
	EP 828754	B1	20050202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	JP 10510511	T2	19981013	JP 1995-511175	19950529
	JP 3133073	B2	20010205	JP 1996-511175	19950529
	AT 288444	E	20050215	AT 1995-918123	19950529
	ES 2235171	T3	20050701	ES 1995-918123	19950529
	NO 9602162	A	19961202	NO 1996-2162	19960528
	AU 9654554	A1	19961212	AU 1996-54554	19960528
	CN 1143647	A	19970226	CN 1996-107637	19960528
	US 5936089	A	19990810	US 1997-973268	19971126
	FI 9704368	A	19971128	FI 1997-4368	19971128
PRAI	WO 1995-IB333	A	19950508		
	WO 1995-IB410	W	19950529		

OS MARPAT 126:104431
GI



I



II

AB Title compds. I [Z = COCR1R2cLCOANR4R5; L = NR6, O, CH2; W = H; W and X = benzo fusion substituted with 0-3 R3a, TR3b, or R12; Y = H, C1-6 alkyl, C4-10 cycloalkyl, aryl-K, phenyl-(C1-6alkyl)-K, thienyl-(C1-6 alkyl)-K substituted with 0-3 R3a, R3b, or R12; K = bond, O, S(O)m, NR2a; X = OR2, R50MN(Aryl), R8R9NCO, R2bO2C, (un)substituted carbo- or heterobicyclic ring; R1 = (un)substituted C1-10 alkyl, aryl, etc.; R2c = H, C1-6 alkyl, C3-7 cycloalkyl; CR1R3c = (un)substituted C3-8 ring; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R2a = H, C1-6 alkyl; R2b = H, C1-8 alkyl, C1-8 halogenated alkyl, C3-8 cycloalkyl, alkylaryl, aryl; R3a, R12 = independently H, halo, Me, OMe, CF3; T = bond, phenylene, 5- or 6-membered heterocycle containing 1-3 hetero atoms; R3b = H, CONR8R9, SO2R8R9, CO2H, CO2(C1-6 alkyl), NR2SO2R9, NR2CONR8R9, NR2SO2NR8R9, NR2COR9, imidazolyl, thiazolyl, tetrazolyl; R4, R5 = independently H, (un)substituted C1-6 alkyl; R6 = H, C1-6 alkyl; R6CR2c = C3-8 ring; R50 = (un)substituted morpholino, piperazino, C3-7 cycloalkyl, C1-6 alkyl; M = CO, SO2; A = bond, Z1(CH2)xCR7R7a(CH2)y; Z1 = NR2, O, bond; R7, R7a = independently H, CF3, Ph, (un)substituted C1-6 alkyl; R8 = H, (un)substituted C1-6 alkyl; R9 = H, (un)substituted C1-6 alkyl, Ph, thiazolyl, imidazolyl, furyl, thienyl], are growth hormone releasing peptide mimics. Heterocyclic dipeptide derivs. I are useful for the treatment and prevention of osteoporosis (no data). Thus, condensation of Boc-D-Ser(CH2Ph)-OH (Boc = Me3CO2C) with 4-(2-oxo-1-benzimidazolinyl)piperidine, followed by deprotection, coupling with BocNHCMe2CO2H, and deprotection with HCl gave dipeptide amide salt II.

L11 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:26293 CAPLUS
DN 126:60362
TI Preparation of heterocyclic dipeptide derivatives which promote release of growth hormone
IN Carpino, Philip A.; Jardine DaSilva, Paul A.; Lefker, Bruce A.; Ragan, John A.
PA Pfizer, Inc., USA
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9635713	A1	19961114	WO 1995-IB333	19950508
	W: CA, FI, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9654554	A1	19961212	AU 1996-54554	19960528
PRAI	WO 1995-IB333	A	19950508		
	WO 1995-IB410	A	19950529		

OS MARPAT 126:60362
GI



I



II

AB Title compds. I [Z = COCR1R2cLCOANR4R5; L = NR6, O, CH2; W = H; W and X = benzo fusion optionally substituted with 1-3 R3a, TR3b, or R12; Y = H, C1-6 alkyl, C3-10 cycloalkyl, aryl optionally substituted with 1-3 R3a, R3b, or R12; X = OR2, R50MN(Aryl), R8R9NCO, R2bO2C, optionally substituted carbobicyclic or heterobicyclic ring; R1 = optionally substituted C1-10 alkyl, aryl, etc.; R2c = H, C1-6 alkyl, C3-7 cycloalkyl; CR1R3c = optionally substituted C3-8 ring; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R2a = H, C1-6 alkyl; R2b = H, C1-8 alkyl, C1-8 halogenated alkyl, C3-8 cycloalkyl, alkylaryl, aryl; R3a, R12 = independently H, halo, Me, OMe, CF3; T = bond, phenylene, 5- or 6-membered heterocycle containing 1-3 hetero atoms; R3b = H, CONR8R9, SO2R8R9, CO2H, CO2(C1-6 alkyl), NR2SO2R9, NR2CONR8R9, NR2SO2NR8R9, NR2COR9, imidazolyl, thiazolyl, tetrazolyl; R4, R5 = independently H, optionally substituted C1-6 alkyl; R6 = H, C1-6 alkyl; R6CR2c = C3-8 ring; R50 = optionally substituted morpholino, piperazino, C3-7 cycloalkyl, C1-6 alkyl; M = CO, SO2; A = bond, Z1(CH2)xCR7R7a(CH2)y; Z1 = NR2, O, bond; R7, R7a = independently H, CF3, Ph, optionally substituted C1-6 alkyl; R8 = H, optionally substituted C1-6 alkyl; R9 = H, optionally substituted C1-6 alkyl, Ph, thiazolyl, imidazolyl, furyl, thienyl], are growth hormone releasing peptide mimics. Heterocyclic dipeptide derivs. I are useful for the treatment and prevention of osteoporosis. Thus, condensation of Boc-D-Ser(CH2Ph)-OH (Boc = Me3CO2C) with 4-(2-oxo-1-benzimidazolinyl)piperidine, followed by deprotection, coupling with BocNHCMe2CO2H, and deprotection with HCl gave dipeptide amide salt II.

L11 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:15489 CAPLUS
DN 126:74755
TI Preparation and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands
IN Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.
PA Eli Lilly and Company, USA
SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 383,823,abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5576321	A	19961119	US 1995-468900	19950606
CA 2210220	AA	19960725	CA 1996-2210220	19960111
WO 9622290	A1	19960725	WO 1996-US41	19960111
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9646516	A1	19960807	AU 1996-46516	19960111

	AU 718875	B2	20000420		
	BR 9607077	A	19971118	BR 1996-7077	19960111
	CN 1178530	A	19980408	CN 1996-192598	19960111
	JP 10512861	T2	19981208	JP 1996-522282	19960111
	EP 722941	A2	19960724	EP 1996-300286	19960115
	EP 722941	A3	20000412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	NO 9703281	A	19970908	NO 1997-3281	19970715
	FI 9703024	A	19970716	FI 1997-3024	19970716
PRAI	US 1995-373823	B2	19950117		
	US 1995-468900	A	19950606		
	WO 1996-US41	W	19960111		

OS MARPAT 126:74755

GI



I II

AB Title compds. [I; A = atoms to complete an N-containing heterocyclic ring; R1 = (CH2)rCHR2CH2(CH2)sR; R = alkylamino, azinylamino, N-attached heterocyclyl, etc.; R2 = H, OH, OMe, Ph; r = 0-4; s = 0-1] were prepared as 5-HT1A receptor ligands (no data). Thus, (S)-4-oxiranylmethoxy-1H-indole was aminated by 4-amino-1-benzylpiperidine to give title compound (S)-II.

L11 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:509758 CAPLUS

DN 125:168021

TI Preparation of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists

IN Audia, James E.; Hibschman, David J.; Krushinski, Jr Joseph H.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.

PA Eli Lilly and Co., USA

SO Eur. Pat. Appl., 112 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 722941	A2	19960724	EP 1996-300286	19960115
	EP 722941	A3	20000412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5576321	A	19961119	US 1995-468900	19950606
PRAI	US 1995-373823	A	19950117		
	US 1995-468900	A	19950606		

OS MARPAT 125:168021

GI



I



II



III

AB The title compds. [I; r = 0-4; s = 0-1; D = pyrrolo, imidazo, etc.; X = H, Ph; R = piperazino, piperidinyl, morpholino, etc.], useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression, anxiety, hypertension, etc., were prepared and formulated. Thus, refluxing of indole II with 4-amino-1-benzylpiperidine in MeOH for 18 h afforded 78% desired product III. In general, compds. I are effective at 20-25 mg/day.

L11 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:608915 CAPLUS
DN 89:208915
TI Psychotropic agents. 3. 4-(4-Substituted piperidinyl)-1-(4-fluorophenyl)-1-butanones with potent neuroleptic activity
AU Sato, Makoto; Arimoto, Masahiro; Ueno, Katsujiro; Kojima, Hiroshi; Yamasaki, Terukiyo; Sakurai, Takeo; Kasahara, Akira
CS Res. Inst., Daiichi Seiyaku Co., Ltd., Tokyo, Japan
SO Journal of Medicinal Chemistry (1978), 21(11), 1116-20
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I, X=  II, X=  III, X= 



IV

AB I [R = C(CO2H), C(COMe), and N], II, III, and IV synthesized by cyclocondensation reactions of substituted 4-(2-aminmoanilino)piperidines were tested for neuroleptic activity. 4-[4-(2,3-Dihydro-2-thioxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone [57648-21-2] was the most potent with activity almost equal to the reference drugs, benperidol and haloperidol. Structure-activity relationships are discussed.

=> d hitstr 15

L11 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 68336-70-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tranquilizing activity of)
RN 68336-70-9 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

=> d hitstr 14

L11 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 13

L11 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

RN 180157-24-8 CAPLUS

CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)

RN 180160-84-3 CAPLUS

CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 12

L11 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

IT 185056-64-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and growth hormone releasing activity of heterocyclic dipeptide derivs.)

RN 185056-64-8 CAPLUS

CN 4-Piperidinecarboxamide, N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 185055-90-7P 185056-26-2P 185056-49-9P
185056-50-2P 185056-55-7P 185056-73-9P
185056-77-3P 185056-80-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and growth hormone releasing activity of heterocyclic dipeptide derivs.)

RN 185055-90-7 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-26-2 CAPLUS
CN Propanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-49-9 CAPLUS
CN Propanamide, 2-amino-N-[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185056-50-2 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-55-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-73-9 CAPLUS
CN Butanamide, 3-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-3-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-methyl-N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-80-8 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 180160-84-3P 185057-43-6P 185058-28-0P
185058-33-7P 185058-92-8P 185058-93-9P
185059-01-2P 185059-11-4P 185059-29-4P
185059-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and growth hormone releasing activity of heterocyclic dipeptide derivs.)

RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 185057-43-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185058-28-0 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 185058-33-7 CAPLUS
CN Carbamic acid, [2-[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185058-92-8 CAPLUS
CN Carbamic acid, [2-[[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 185058-93-9 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-01-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-11-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-29-4 CAPLUS
CN Carbamic acid, [3-[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-

benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-37-4 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 11

L11 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 185055-90-7P 185056-26-2P 185056-50-2P
185056-55-7P 185056-64-8P 185056-73-9P
185056-77-3P 185056-80-8P 185961-75-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of growth hormone-releasing dipeptides)
RN 185055-90-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-26-2 CAPLUS
CN Propanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-50-2 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-55-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-64-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-73-9 CAPLUS
CN Butanamide, 3-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-3-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-methyl-N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185056-80-8 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 185961-75-5 CAPLUS
CN Propanamide, 2-amino-N-[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 180160-84-3P 185057-43-6P 185058-28-0P
185058-33-7P 185058-93-9P 185059-01-2P
185059-11-4P 185059-29-4P 185059-37-4P
185962-11-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of growth hormone-releasing dipeptides)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 185057-43-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185058-28-0 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA

INDEX NAME)



RN 185058-33-7 CAPLUS
CN Carbamic acid, [2-[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185058-93-9 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-01-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-11-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-29-4 CAPLUS
CN Carbamic acid, [3-[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-37-4 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185962-11-2 CAPLUS
CN Carbamic acid, [2-[[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 10

L11 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 9

L11 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 8

L11 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 7

L11 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (αS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT 180160-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180160-84-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-(4-piperidinyl)- (9CI) (CA INDEX NAME)



=> d hitstr 6

L11 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 258287-19-3P 258287-20-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists)
RN 258287-19-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 258287-20-6 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-,

dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

=> d hitstr 5

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
IT 569355-84-6P 569355-85-7P 569355-87-9P
569355-88-0P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid-phase synthesis of benzimidazole libraries biased for RNA binding using Wang resin or Rink amide resin)
RN 569355-84-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[1-(ethoxycarbonyl)-4-piperidinyl]-2-(3-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-85-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(4-chloro-3-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-87-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(5-chloro-2-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-88-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(2-chloro-5-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 569355-55-1P 569355-56-2P 569355-58-4P
569355-59-5P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)

(solid-phase synthesis of benzimidazole libraries biased for RNA binding using Wang resin or Rink amide resin)

RN 569355-55-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-[1-(ethoxycarbonyl)-4-piperidinyl]-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 569355-56-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-(4-chloro-3-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 569355-58-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-(5-chloro-2-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 569355-59-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(2-chloro-5-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 5

L11 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:215662 CAPLUS
DN 139:133505
TI Solid-phase synthesis of benzimidazole libraries biased for RNA targets
AU Vourloumis, Dionisios; Takahashi, Masayuki; Simonsen, Klaus B.; Ayida, Benjamin K.; Barluenga, Sofia; Winters, Geoffrey C.; Hermann, Thomas
CS Department of Medicinal Chemistry, Anadys Pharmaceuticals, Inc., San Diego, CA, 92121, USA
SO Tetrahedron Letters (2003), 44(14), 2807-2811
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 139:133505
GI



AB An efficient and highly versatile synthesis of two libraries I (R1 = 3-pyridylmethyl, CH2CH2NMe2, N-morpholinylethyl, etc., R2 = 3-O2NC6H4, 3-pyridyl, 2-O2N-3-ClC6H3, etc.) and II [R = 4-C6H4CH2, (CH2)5, CH2, etc., R1 = CH2CH2CO2Et, N-morpholinylethyl, 5-methyl-2-furylmethyl, etc., R2 = 2-Cl-6-O2NC6H3, 3-thienyl, 2-Cl-5-O2N-C6H3, etc.; R2 = cyclohexyl, Et, PhCH2] based on the privileged benzimidazole scaffold is described. Our design is aimed at obtaining mols., biased for binding to RNA targets, by incorporating functionalities, which are frequently found in natural

RNA-ligands. The library construction was realized with the use of SPOS (solid-phase organic synthesis) using either the Wang resin or the Rink amide resin in high average yields and purity. Monitoring and quantitation of intermediates and final products were performed by the use of NMR spectroscopy using DMFu as an internal standard

IT 569355-84-6P 569355-85-7P 569355-87-9P
569355-88-0P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid-phase synthesis of benzimidazole libraries biased for RNA binding using Wang resin or Rink amide resin)

RN 569355-84-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[1-(ethoxycarbonyl)-4-piperidinyl]-2-(3-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-85-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(4-chloro-3-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-87-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(5-chloro-2-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569355-88-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(2-chloro-5-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 569355-55-1P 569355-56-2P 569355-58-4P
569355-59-5P
RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase synthesis of benzimidazole libraries biased for RNA binding using Wang resin or Rink amide resin)
RN 569355-55-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-[1-(ethoxycarbonyl)-4-piperidinyl]-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 569355-56-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(4-chloro-3-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 569355-58-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(5-chloro-2-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 569355-59-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-(2-chloro-5-nitrophenyl)-1-[1-(ethoxycarbonyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=10/11/12
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 11 9
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 08:57:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18139 TO ITERATE

100.0% PROCESSED 18139 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.01

L3 15 SEA SSS FUL L1

=> d scan

L3 15 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[2-(2-phenylethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-5-yl]-, (2E)- (9CI)
MF C30 H32 N4 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.26	168.47

FILE 'CAPLUS' ENTERED AT 08:57:54 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 18 Sep 2006 (20060918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 6 L3

=> d bib abs hitstr 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:283471 CAPLUS
DN 142:355265
TI Preparation of benzimidazolylhydroxamates as inhibitors of histone deacetylase (HDAC).
IN Chen, Dizhong; Deng, Weiping; Sangthongpitag, Kanda; Song, Hong Yan; Sun, Eric T.; Yu, Niefang; Zou, Yong
PA Sbio Pte Ltd, Singapore
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005028447	A1	20050331	WO 2004-SG307	20040921

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004274382	A1	20050331	AU 2004-274382	20040921
CA 2539766	AA	20050331	CA 2004-2539766	20040921
EP 1673349	A1	20060628	EP 2004-775628	20040921

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-504214P	P	20030922	
US 2003-530890P	P	20031222	
WO 2004-SG307	W	20040921	

OS MARPAT 142:355265

GI



I

AB Title compds. [I; R1 = H, (substituted) alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, amino, etc.; R2 = H, halo, (substituted) alkyl, alkenyl, alkynyl, haloalkyl, aryl, heteroaryl, amino, etc.; R3 = H, alkyl, acyl, Na, Ca, Mg; X, Y = H, halo, cyano, NO2, CF3, OCF3, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, cycloalkyl, cycloalkenyl, alkoxy, aryl, heteroaryl, etc.; R4 = H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, aralkyl, heteroaralkyl, acyl; Z = bond, CH2, CH2CH2, CH:CH, (substituted) cycloalkylene; with provisos], were prepared Thus, Me trans-4-(3-hydroxypropylamino)-3-nitrocinnamate (preparation given), 3-phenylbutyraldehyde, and tin chloride were heated together in HOAc at 45° for 17 h to give 34.9% Me 3-[1-(3-hydroxypropyl)-2-(2-phenylpropyl)-1H-benzimidazol-5-yl]acrylate. This was stirred with NH2OH.HCl in MeOH to give 6% N-hydroxy-3-[1-(3-hydroxypropyl)-2-(2-phenylpropyl)-1H-benzimidazol-5-yl]acrylamide. The latter inhibited HDAC1 with IC50 = 0.051 μM.

IT 849059-38-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of benzimidazolylhydroxamates as inhibitors of histone deacetylase)

RN 849059-38-7 CAPLUS

CN 2-Propenamide, N-hydroxy-3-[2-(2-phenylethyl)-1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:855801 CAPLUS
DN 139:350734
TI Preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists
IN Zeng, Qingbei; Aslanian, Robert G.; Berlin, Michael Y.; Boyce, Christopher W.; Cao, Jianhua; Kozlowski, Joseph A.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.; Shih, Neng-Yang; Solomon, Daniel M.; Tom, Wing C.
PA Schering Corporation, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088967	A1	20031030	WO 2003-US11672	20030416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481940	AA	20031030	CA 2003-2481940	20030416
	AU 2003223627	A1	20031103	AU 2003-223627	20030416
	US 2004097483	A1	20040520	US 2003-417391	20030416
	US 7105505	B2	20060912		
	EP 1499316	A1	20050126	EP 2003-719766	20030416
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009348	A	20050301	BR 2003-9348	20030416
	CN 1658874	A	20050824	CN 2003-813779	20030416
	JP 2005529116	T2	20050929	JP 2003-585719	20030416
	ZA 2004007984	A	20051018	ZA 2004-7984	20041004
	NO 2004005002	A	20050118	NO 2004-5002	20041117
PRAI	US 2002-373731P	P	20020418		
	US 2002-373467P	P	20020418		
	WO 2003-US11672	W	20030416		

OS MARPAT 139:350734
GI



I



II

AB The title compds. [I; R1 = (un)substituted benzimidazolyl or a derivative thereof; R2 = (un)substituted aryl or heteroaryl; M1, M2 = CR3, N; X = a bond, alkylene; Y = CO, CS, SO2, etc.; Z = a bond, alkylene, CO, etc.; R3 = H, halo, alkyl, etc.; R12 = alkyl, OH, alkoxy, etc.; R13 = alkyl, alkoxy, OH, etc.; a, b = 0-2; n, p = 1-3; r = 0-3; with the provisos] which are histamine H3 antagonists, were prepared E.g., a multi-step synthesis of II which showed Ki of 1 nM in rHu H3 binding assay, was given. Also disclosed are pharmaceutical compns. comprising the compds. of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I. Also disclosed are methods of treating said diseases or conditions using the compds. of formula I in combination with an H1 receptor antagonist.

IT 618892-87-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)

RN 618892-87-8 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(phenylmethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:737751 CAPLUS

DN 139:261330

TI Preparation of benzodiazepine-substituted piperidines for use in treating

cardiovascular diseases

IN Hurnaus, Rudolf; Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Gerlach, Kai; Schindler, Marcus; Arndt, Kirsten; Bauer, Eckhart

PA Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany; et al.

SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076432	A1	20030918	WO 2003-EP2417	20030310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10211770	A1	20031002	DE 2002-10211770	20020314
	CA 2476031	AA	20030918	CA 2003-2476031	20030310
	AU 2003212323	A1	20030922	AU 2003-212323	20030310
	EP 1487821	A1	20041222	EP 2003-708202	20030310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005527519	T2	20050915	JP 2003-574649	20030310
	US 2003236282	A1	20031225	US 2003-388273	20030313
	US 7026312	B2	20060411		
	US 2005215546	A1	20050929	US 2005-138868	20050526
PRAI	DE 2002-10211770	A	20020314		
	US 2002-396660P	P	20020717		
	WO 2003-EP2417	W	20030310		
	US 2003-388273	A1	20030313		

OS MARPAT 139:261330

GI



I



II

AB Title compds. I [R = (un)substituted 5-7-membered aza-, diaza-, triaza-oxaaza- thiaza- thiadiaza-heterocycle; X = O, (un)substituted NH, :NCN, :NSO2R1; Z = (un)substituted CH2, NH; A = (un)substituted CH; n = 1, 2; R1 = alkyl, (un)substituted Ph; R2 = substituted Ph; R3, R4 = H, (un)substituted alkyl, Ph, naphthyl, heterocyclic; R5 = H, (un)substituted alkyl, OH, naphthyl, heteroaryl, cycloalkyl] were prepared for use as CGRP antagonists (no data). Thus, the title compound II was prepared by cyclizing the benzodiazepinylpiperidinylcarbonylaminopropionic acid fragment with 2-Me2N(CH2)3C6H4NH2 to form the benzimidazole moiety.

IT 600724-44-5P 600724-56-9P 600724-63-8P
600724-71-8P 600724-75-2P 600724-81-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzodiazepine-substituted piperidines for use in treating cardiovascular diseases)

RN 600724-44-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-2-(4-amino-3,5-dibromophenyl)-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 600724-56-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-(3,5-dibromo-4-hydroxyphenyl)-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 600724-63-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-(3,4-dibromophenyl)-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 600724-71-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-(3,4-diethylphenyl)-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 600724-75-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 600724-81-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-1-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]ethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:573269 CAPLUS
DN 135:152805
TI Preparation of benzimidazoles as ORL1-receptor agonists for analgesics
IN Ito, Fumitaka; Noguchi, Hirohide; Ohashi, Yoriko; Shimokawa, Hirohisa
PA Pfizer Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001213878	A2	20010807	JP 2000-396414	20001227

	JP 3392402	B2	20030331		
	EP 1122257	A1	20010808	EP 2000-311316	20001218
	EP 1122257	B1	20051012		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AT 306488	E	20051015	AT 2000-311316	20001218
	ES 2249237	T3	20060401	ES 2000-311316	20001218
	CA 2330092	AA	20010705	CA 2001-2330092	20010103
	CA 2330092	C	20050322		
	US 2002049212	A1	20020425	US 2001-753954	20010103
	US 6861425	B2	20050301		
	BR 2001000014	A	20010828	BR 2001-14	20010104
PRAI	US 2000-174542P	P	20000105		

OS MARPAT 135:152805

GI



I

AB Title compds. I [R1 = C3-11 cycloalkyl, C6-16 bicycloalkyl, C6-16 tricycloalkyl, C8-16 tetracycloalkyl, etc.; A = (un)substituted C1-7 alkyl, C2-5 alkenyl, C2-5 alkynyl, aryl, etc.; M = single bond, CH2,O, S, SO, SO2, CO, NH, etc.; Y = 4- to 12-membered bicyclic carbon ring, 4- to 12- membered bicyclic hetero ring, 5- to 17-membered spiro carbon ring, 5- to 17-membered spiro hetero ring; Z1-Z4 = (un)substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylsulfonyl, C1-4 alkylcarbonyl, carboxy, etc.] or their salts are prepared Tert-Bu 3-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was treated with F3CCO2H in CH2Cl2 at room temperature for 0.5 h to give 77.6% 2-(3,8-diazabicyclo[3.2.1]oct-3-yl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazole HCl salt.

IT 352541-90-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazoles as ORL1-receptor agonists for analgesics)

RN 352541-90-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 352542-52-0P 352542-53-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles as ORL1-receptor agonists for analgesics)
RN 352542-52-0 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-methyl-5-[[1-[4-phenyl-1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 352542-53-1 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-methyl-5-[[1-[4-phenyl-1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:117042 CAPLUS
DN 132:151821
TI Preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor

agonists.

IN Ito, Fumitaka; Noguchi, Hirohide; Kondo, Hiroshi

PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.

SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008013	A2	20000217	WO 1999-IB1239	19990705
	WO 2000008013	A3	20000323		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 513424	B	20021211	TW 1999-88110899	19990628
	CA 2339621	AA	20000217	CA 1999-2339621	19990705
	CA 2339621	C	20050405		
	AU 9943859	A1	20000228	AU 1999-43859	19990705
	AU 749166	B2	20020620		
	EP 1102762	A2	20010530	EP 1999-926688	19990705
	EP 1102762	B1	20021113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200100403	T2	20010723	TR 2001-200100403	19990705
	BR 9912778	A	20010925	BR 1999-12778	19990705
	EE 200100075	A	20020617	EE 2001-75	19990705
	JP 2002522431	T2	20020723	JP 2000-563646	19990705
	JP 3367945	B2	20030120		
	AT 227716	E	20021115	AT 1999-926688	19990705
	PT 1102762	T	20030228	PT 1999-926688	19990705
	ES 2185357	T3	20030416	ES 1999-926688	19990705
	NZ 509299	A	20030530	NZ 1999-509299	19990705
	US 6172067	B1	20010109	US 1999-369208	19990805
	ZA 2001000900	A	20020603	ZA 2001-900	20010201
	HR 2001000089	A1	20020228	HR 2001-89	20010202
	HR 20010089	B1	20030430		
	NO 2001000603	A	20010405	NO 2001-603	20010205
	BG 105301	A	20011231	BG 2001-105301	20010301
	US 2003109549	A1	20030612	US 2002-283604	20021030
PRAI	WO 1998-IB1206	W	19980806		
	WO 1999-IB1239	W	19990705		
	US 1999-369208	A3	19990805		
	US 2000-676245	B1	20000929		

OS MARPAT 132:151821

GI



I

AB Title compds. [I; R = (substituted) mono-, di-, tri-, or tetracycloalkyl; A = alkyl, haloalkyl, alkenyl, alkynyl, (substituted) phenylalkyl, aryl, heteroaryl, heterocyclyl; Y = H, halo, amino, SH, (substituted) alkyl-M, cycloalkyl-M, alkenyl-M, alkyl-NH-alkyl-M, dialkyl-N-alkyl-M, aryl-M, heterocyclyl-M, arylalkyl-M, etc.; M = bond, O, S, NH S, SO, SO2, etc.; Z1-Z4 = H, halo, alkyl, haloalkyl, alkoxy, alkylsulfonyl, alkylcarbonyl, CO2H, amino, H2NCO, Ph, naphthyl, etc.], were prepared as ORL1 receptor agonists (no data). Thus, 2-chloro-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]benzimidazole (preparation given) was stirred with MeNH2 in MeOH in an autoclave at 110° for 6 h to give N-methyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-amine.

IT 258287-21-7P 258287-22-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists)

RN 258287-21-7 CAPLUS

CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 258287-22-8 CAPLUS

CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1975:24123 CAPLUS
DN 82:24123
TI Two-photon absorption spectra of organic dye molecules
AU Aslanidi, E. B.; Tikhonov, E. A.
CS USSR
SO Optika i Spektroskopiya (1974), 37(4), 784-5
CODEN: OPSPAM; ISSN: 0030-4034
DT Journal
LA Russian
AB One- and 2-photon absorption spectra were given of Rhodamine 6G and imidocarbocyanine in alc. solns. by using the fluorescence method. The 2-photon absorption spectra of the both compds. showed 2 principal maximum, one coinciding with the vibronic transition of the short-wave wing of the long-wave one-photon absorption band and the other falling upon the region of one-photon transition to higher singlet states. The spectral dependence of 2-photon absorption probability was qual. discussed.
IT 54375-46-1
RL: PRP (Properties)
(photon absorption by, single and multi-)
RN 54375-46-1 CAPLUS
CN 1H-Benzimidazolium, 2-[3-[1,3-dihydro-1,3-bis(3,4,5,6-tetrahydro-2-pyridinyl)-2H-benzimidazol-2-ylidene]-1-propenyl]-1,3-bis(3,4,5,6-tetrahydro-2-pyridinyl)-, iodide (9CI) (CA INDEX NAME)



● I^-

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

```
     (FILE 'HOME' ENTERED AT 07:18:08 ON 19 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 07:18:30 ON 19 SEP 2006
L1                 STRUC
L2               9 S L1
L3                 STRUC
L4               0 S L3
L5               0 S L3 FUL
L6                 STRUC
L7               4 S L6
L8                 STRUC
L9               0 S L8
L10                STRUC
L11              0 S L10
L12              2 S L10 FUL
L13                STRUC
L14              0 S L13
L15              5 S L13 FUL
L16              3 S L15 NOT L12

     FILE 'CAPLUS' ENTERED AT 07:25:49 ON 19 SEP 2006
L17              2 S L15
L18            ANALYZE L17 2 RN :     134 TERMS

     FILE 'REGISTRY' ENTERED AT 07:26:57 ON 19 SEP 2006
L19            134 S L18
L20              1 S L19 AND  C18 H17 N7 O3 S . CL H/MF

     FILE 'CAPLUS' ENTERED AT 07:30:34 ON 19 SEP 2006
L21              1 S L20
L22           6068 S DEACETYLASE
L23             59 S L22 AND PURIN?

     FILE 'STNGUIDE' ENTERED AT 07:33:33 ON 19 SEP 2006

     FILE 'CAPLUS' ENTERED AT 07:42:54 ON 19 SEP 2006
L24             25 S L23 AND US/PC
L25            ANALYZE L24 12 RN :     649 TERMS

     FILE 'REGISTRY' ENTERED AT 07:50:01 ON 19 SEP 2006
L26            649 S L25
L27              8 S L26 AND PURIN?

     FILE 'CAPLUS' ENTERED AT 07:50:42 ON 19 SEP 2006
L28            399 S L27
L29              1 S L28 AND L24
```

AN 2004:589250 CAPLUS
DN 141:140470
TI Preparation of aminophenylbenzamides as inhibitors of histone deacetylase
IN Delorme, Daniel; Zhou, Zhihong
PA Methylgene, Inc., Can.
SO U.S. Pat. Appl. Publ., 318 pp., Cont.-in-part of U.S. Ser. No. 242,304.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142953	A1	20040722	US 2003-358556	20030204 <--
	US 6897220	B2	20050524		
	US 2004106599	A1	20040603	US 2002-242304	20020912 <--
	AU 2004210016	A1	20040819	AU 2004-210016	20040204
	CA 2515338	AA	20040819	CA 2004-2515338	20040204
	WO 2004069823	A1	20040819	WO 2004-CA139	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1590340	A1	20051102	EP 2004-707852	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1723207	A	20060118	CN 2004-80001769	20040204
	BR 2004007195	A	20060214	BR 2004-7195	20040204
	JP 2006514998	T2	20060518	JP 2005-518241	20040204
	US 2006058298	A1	20060316	US 2005-81095	20050315 <--
	JP 2005255683	A2	20050922	JP 2005-80310	20050318
	US 2005288282	A1	20051229	US 2005-91025	20050325 <--
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	US 2002-242304	A2	20020912		
	JP 2003-528544	A3	20020912		
	US 2003-358556	A	20030204		
	WO 2004-CA139	W	20040204		

OS MARPAT 141:140470
GI



I

Q1 =



Q2 =



Q3 =



AB Title compds. e.g. (I; Y, Z = N, CH; W = Q1, Q2, Q3, etc.), were prepared Thus, 4-[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino]methyl]benzoic acid (preparation given) in DMF was stirred with Et3N, BOP, and 1,2-phenylenediamine to give 63% 4-[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino]methyl]-N-(2-aminophenyl)benzamide. The latter inhibited human histone deacetylase HDAC-1 with IC50 = 0.4 μM.

IT 503040-08-2P, N-(2-Aminophenyl)-4-[[[2-chloro-9-(2-methoxyethyl)-9H-purin-6-yl]amino]methyl]benzamide 503042-82-8P, N-(2-Aminophenyl)-4-((2-amino-9-butyl-9H-purin-6-ylamino)methyl)benzamide 503042-83-9P, N-(2-Aminophenyl)-4-((2-amino-9H-purin-6-ylamino)methyl)benzamide 503042-84-0P, N-(2-Aminophenyl)-4-((2-chloro-9H-purin-6-ylamino)methyl)benzamide 503042-85-1P, N-(2-Aminophenyl)-4-((9-butyl-2-chloro-9H-purin-6-ylamino)methyl)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminophenylbenzamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503040-08-2 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[[2-chloro-9-(2-methoxyethyl)-9H-purin-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 503042-82-8 CAPLUS
CN Benzamide, 4-[[(2-amino-9-butyl-9H-purin-6-yl)amino]methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)



RN 503042-83-9 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[(2-amino-1H-purin-6-yl)amino]methyl]-
(9CI) (CA INDEX NAME)



RN 503042-84-0 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[(2-chloro-1H-purin-6-yl)amino]methyl]-
(9CI) (CA INDEX NAME)



RN 503042-85-1 CAPLUS
CN Benzamide, N-(2-aminophenyl)-4-[[(9-butyl-2-chloro-9H-purin-6-yl)amino]methyl]- (9CI) (CA INDEX NAME)



IT 5451-40-1, 2,6-Dichloro-9H-purine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminophenylbenzamides as inhibitors of histone deacetylase for treating cell proliferative disorders)
RN 5451-40-1 CAPLUS
CN 1H-Purine, 2,6-dichloro- (9CI) (CA INDEX NAME)






```
VAR G1=10/11/12
ENTER (DIS), GRA, NOD, BON OR ?:end
L1   STRUCTURE CREATED

=> s l1
SAMPLE SEARCH INITIATED 10:18:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      250 TO ITERATE

100.0% PROCESSED      250 ITERATIONS                                  9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          4052 TO     5948
PROJECTED ANSWERS:                9 TO      359

L2             9 SEA SSS SAM L1
```

```
=> s   l2 and (C29 H25 Cl N8/mf or  C23 H33 N7 O2/mf)
             2 C29 H25 CL N8/MF
            71 C23 H33 N7 O2/MF
L3           2 L2 AND (C29 H25 CL N8/MF OR  C23 H33 N7 O2/MF)

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      12.16      12.37

FILE 'CAPLUS' ENTERED AT 10:20:37 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 Sep 2006  VOL 145 ISS 13
FILE LAST UPDATED: 18 Sep 2006  (20060918/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4           2 L3

=> d bib abs hitstr 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:964997  CAPLUS
DN   141:410816
TI   Preparation of azaheterocyclyl-substituted diphenylpyridines as Akt
     inhibitors for the treatment of cancer
IN   Bilodeau, Mark T.; Duggan, Mark E.; Hartnett, John C.; Lindsley, Craig W.;
     Wu, Zhicai; Zhao, Zhijian
PA   Merck & Co., Inc., USA
SO   PCT Int. Appl., 98 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004096131        A2    20041111    WO 2004-US12188         20040420
     WO 2004096131        A3    20051103
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
```

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2004233828	A1	20041111	AU 2004-233828	20040420
	CA 2522431	AA	20041111	CA 2004-2522431	20040420
	EP 1622616	A2	20060208	EP 2004-760294	20040420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1809354	A	20060726	CN 2004-80017118	20040420
PRAI	US 2003-465260P	P	20030424		
	WO 2004-US12188	W	20040420		

OS MARPAT 141:410816

GI



I



II

AB Azaheterocyclyl-substituted diphenylpyridines I [uppermost nitrogen-containing ring is a heterocycle; R1, R2, R5 = (un)substituted alkyl, aryl, heteroaryl, alkenyl, alkynyl, HO2C, NC, halo, HO, OHC, O2N, alkoxy, etc.; R3, R4 = H, alkyl, perfluoroalkyl; R3, R4, and the carbon to which they are bonded may form a carbocycle or a heterocycle containing O, S, S(:O), SO2, (un)substituted N or NHC(:O); n = 0-3; p = 0-2; q = 0-3] such as II are prepared as inhibitors of Akt1, Akt2, or Akt3 for the treatment of cancer alone or in conjunction with other drugs or radiation therapy. Trifluorosulfonylation of 6-hydroxy-5-phenyl-3-pyridinecarbonitrile, palladium-catalyzed Suzuki coupling with 4-formylphenylboronic acid, and reductive amination of the aldehyde with 1-(4-piperidinyl)-2,3-dihydro-2-benzimidazolone yields II as its TFA salt. I inhibit one or more of Akt1, Akt2, or Akt3 with IC50 values of ≤ 50 μM (no data).

IT 791851-00-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compound; preparation of azaheterocyclyl-substituted

diphenylpyridines as Akt inhibitors for the treatment of cancer)
RN 791851-00-8 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[4-[[4-(6-amino-9H-purin-9-yl)-1-piperidinyl]methyl]phenyl]-2-chloro-5-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:109473 CAPLUS
DN 122:240300
TI Heterocyclic analogs of nucleosides: synthesis and biological evaluation of novel analogs of puromycin
AU Hultin, Philip G.; Szarek, Walter A.
CS Dep. Chem., Queen's Univ., Kingston, ON, K7L 3N6, Can.
SO Canadian Journal of Chemistry (1994), 72(9), 1978-89
CODEN: CJCHAG; ISSN: 0008-4042
DT Journal
LA English
GI



I

AB The diastereomeric 1-(piperidine-3'-yl)uracil compds. and the N6-dimethyl-9-(piperidine-3'-yl)adenine compds. I (R = CH2OH, R1 = uracil, N6-dimethyladenine; R = uracil, N6-dimethyladenine, R1 = CH2OH) have been prepared as analogs of the naturally occurring aminoacyl nucleoside antibiotic puromycin. The diastereomers were separated using HPLC, and the absolute configuration of I were assigned. These puromycin analogs have been tested for anti-HIV and antitumor activity in vitro.
IT 162315-07-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antitumor and antiviral activities of puromycin analogs)
RN 162315-07-3 CAPLUS

CN 3-Piperidinemethanol, 1-[2-amino-3-(4-methoxyphenyl)propyl]-5-[6-(dimethylamino)-9H-purin-9-yl]-, [3S-[1(R*),3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.